Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Common Equity (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Common Equity for 3 consecutive years, with $155.5 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Common Equity rose 4.92% year-over-year to $155.5 million, compared with a TTM value of $155.5 million through Sep 2024, up 4.92%, and an annual FY2023 reading of $162.9 million, up 7.76% over the prior year.
  • Common Equity was $155.5 million for Q3 2024 at Oramed Pharmaceuticals, down from $176.2 million in the prior quarter.
  • Across five years, Common Equity topped out at $176.2 million in Q2 2024 and bottomed at $148.2 million in Q3 2023.
  • Average Common Equity over 3 years is $157.2 million, with a median of $153.1 million recorded in 2022.
  • The sharpest move saw Common Equity dropped 7.44% in 2023, then rose 16.93% in 2024.
  • Year by year, Common Equity stood at $151.2 million in 2022, then grew by 7.76% to $162.9 million in 2023, then fell by 4.53% to $155.5 million in 2024.
  • Business Quant data shows Common Equity for ORMP at $155.5 million in Q3 2024, $176.2 million in Q2 2024, and $165.7 million in Q1 2024.